China Biotech Service and Hong Kong-Shenzhen Innovation and Technology Park Corporation signed a memorandum of understanding
China Biotechnology Service (08037) announced that the Hong Kong-Shenzhen Innovation and Technology Park Limited signed a memorandum of understanding with about 60 partner organizations (including the company), and held the Hong Kong-Shenzhen Innovation and Technology Park partner launch ceremony on April 18, 2024. According to the memorandum of understanding between the company and the Hong Kong-Shenzhen Innovation and Technology Park Corporation, the parties concerned have agreed to cooperate in the development of the Hong Kong-Shenzhen Innovation and Technology Park located in the Lok Ma Chau Hetao area of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone.
It is expected to open the first BNCT boron neutron treatment center in Hong Kong, and the Chinese Medicine Service (08037) wants to enter the Hong Kong-Shenzhen Science and Technology Innovation Park
The reason behind the memorandum of understanding with the Hong Kong-Shenzhen Science and Technology Innovation Park is a concrete reflection of China's biotechnology services speeding up the commercialization process of boron neutron capture therapy.
China Biotechnology Services (08037.HK) signs MOU with Hong Kong-Shenzhen Innovation and Technology Park
Gelonghui, April 18, 丨 China Biotechnology Service (08037.HK) announced that the Hong Kong-Shenzhen Innovation and Technology Park Limited (“Hong Kong-Shenzhen Innovation and Technology Park Corporation”) signed a memorandum of understanding with about 60 partner organizations (including companies), and held the Hong Kong-Shenzhen Innovation and Technology Park partner launch ceremony on April 18, 2024. According to the Memorandum of Understanding between the Company and Hong Kong-Shenzhen Innovation and Technology Park Corporation (collectively referred to as the “parties concerned”), the parties concerned have agreed (among others) to cooperate in the development of the Hong Kong-Shenzhen Innovation and Technology Park in the Lok Ma Chau Hetao area of the Hetao Shenzhen-Hong Kong Science and Technology Cooperation Zone. Development of boron neutron capture in cancer treatment
中國生物科技服務:2023 年報
China Biotechnology Services (08037) achieved revenue of approximately HK$212 million in 2023
China Biotechnology Services (08037) announced its 2023 results, with revenue of approximately HK$212 million and gross profit of 343...
CH BIOTECH SER: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
CH BIOTECH SER: POSTPONEMENT OF BOARD MEETING
Chinese Medicine Services (08037) and Guanhe Pharmaceutical jointly build a joint laboratory in Hong Kong to carry out CRO services
On March 12, 2024, Guanhe Pharmaceutical and China Biotech Services Holdings Limited reached a strategic cooperation to jointly establish the “Zhongsheng Medical Service-Guanhe Joint Laboratory” in Hong Kong.
China Biotechnology Services (08037.HK) Profit Alert: Expected net loss of HK$90 million for the 2023 fiscal year
On February 28, GLONGHUI | China Biotech Services (08037.HK) announced that for the year ended 31 December 2023 (“Fiscal Year 2023”), the Group is expected to record a net loss attributable to the company owner of approximately HK$90 million in fiscal year 2023. Compared with losses, the Group recorded net profit attributable to company owners of approximately HK$258 million in the same period in 2022. The Board believes that the loss recorded was mainly due to (i) the COVID-19 nuclear impact on the Group due to the relaxation and subsequent cancellation of the COVID-19 quarantine regulations imposed by the relevant government authorities
Some China Biotech Services Holdings Limited (HKG:8037) Shareholders Look For Exit As Shares Take 30% Pounding
China Biotech Services Holdings Limited (HKG:8037) shareholders won't be pleased to see that the share price has had a very rough month, dropping 30% and undoing the prior period's positive performanc
Zhongsheng Science Service (08037) and Zhongguancun Technology Leasing (01601) reached a strategic cooperation on financing matters
China Biotechnology Service Holdings Co., Ltd. (“Zhongsheng Science Service”, stock code: 08037) is concerned with the capital requirements and China Customs...
China Biotech Services Holdings Limited's (HKG:8037) Shares Climb 31% But Its Business Is Yet to Catch Up
China Biotech Services Holdings Limited (HKG:8037) shares have had a really impressive month, gaining 31% after a shaky period beforehand. Not all shareholders will be feeling jubilant, since the s
China Biotechnology Service (08037.HK): Shanghai Longyao received a strategic investment of 98 million yuan to promote CAR-T cell therapy and other major business growth opportunities for the Group
On December 9, China Biotech Service (08037.HK) issued an announcement. On December 8, 2023, the company, Shanghai Longyao (an indirect non-wholly owned subsidiary of the company) and the investor Yixing Environmental Science Park Equity Investment Partnership (Limited Partnership) entered into a capital injection agreement of RMB 48 million. According to this (i) investors agreed to make a capital injection of RMB 48 million, of which RMB 2,99,670 was used to subscribe for 5.35% of Shanghai Longyao's registered share capital, and RMB 47.01 million into Shanghai Longyao's share capital reserve. ii) Company Agree (Adopted to be completed in China
Shanghai Longyao Biotech completes 100 million yuan financing to focus on CD20 CAR-T phase II clinical trial
This round of financing was led by the Yixing Environmental Science Park Production and Development Equity Investment Partnership (Limited Partnership), and the controlling shareholder, China Biotech Service, continues to increase.
CH BIOTECH SER: THIRD QUARTERLY REPORT 2023
China Biotech Services (08037.HK) had a net loss of HK$65.976 million in the first three quarters
Gelonghui November 13丨China Biotechnology Service (08037.HK) announced that in the nine months ended September 30, 2023, the Group recorded a turnover of approximately HK$201 million, a sharp decrease of about 84.27% over the previous year. The Group recorded a net loss attributable to company owners of approximately HK$65.976 million, net profit attributable to company owners of HK$160 million for the same period last year, and a basic and diluted loss of HK$0.068 per share.
CH BIOTECH SER: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
China Biotech Services (08037.HK) expects a net loss of approximately HK$65 million in the first three quarters
On October 31, Gelonghui announced that China Biotech Services (08037.HK) announced that it is expected that the Group will record a net loss attributable to company owners of about HK$65 million in the nine months ending September 30, 2023. Compared with losses, the Group recorded a net profit attributable to company owners of the company of approximately HK$160 million in the same period in 2022. The board of directors believes that the loss was mainly due to a decline in demand for the Group's COVID-19 nucleic acid testing services and rapid antigen test kits after the relevant government authorities relaxed COVID-19 quarantine regulations.
Selected GLONGHUI Announcements (Hong Kong Stocks) | Nai Xue's Tea Net New 166 Nai Xue Tea Direct Stores in the Third Quarter
[Today's Focus] Nai Xue's Tea (02150.HK): Nai Xue's Tea Direct Store Nai Xue's Tea (02150.HK) announced that in the third quarter of 2023, during the third quarter, the Group recorded a net addition of 166 Nai Xue's tea directly-managed stores and shut down 5 Nai Xue's tea directly-managed stores. As of September 30, 2023, the Group operated a total of 1,360 directly managed tea stores in Naxue. In addition to Nai Xue's directly managed tea stores, as of September 30, 2023, the group has operated a total of 4 Nai Xue tea franchise stores. Currently, Nai Xue's tea franchise stores are mainly concentrated in the middle and low
China Biotech Services (08037.HK) and AstraZeneca Investment (China) signed a strategic cooperation agreement to cooperate on immunocyte therapy, etc.
Glonghui, Oct. 18, 丨 China Biotech Services (08037.HK) announced that on October 18, 2023, the company and AstraZeneca Investment (China) Co., Ltd. (“AstraZeneca (China)”, together with the company collectively referred to as the “Contractor”) entered into a strategic cooperation framework agreement. Based on this, the contracting parties agreed to develop (i) the improvement, commercialization and licensing rights of immunocyte therapy; (ii) the design, planning and ecological construction of R&D and production sites; and (ii) cooperate with innovative platform models. AstraZeneca (China) has established R&D, production, operation, innovation, and capital in China
No Data